Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukaemia

British Journal of Haematology

Volumn 100, Issue 4, 1998, Pages 629-636

  Uyl De Groot, C A ^a   Lowenberg B ^b   Vellenga, E ^e   Suciu, S ^c   Willemze, R ^d   Rutten, F F H ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Europ Organisation Res Treatm C   (Belgium)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Acute myeloid leukaemia; Costs; Elderly; GM CSF; Quality of life

Indexed keywords

CYTARABINE; DAUNORUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIARRHEA; ECZEMA; FEMALE; FOLLOW UP; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; STATISTICAL ANALYSIS;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COST-BENEFIT ANALYSIS; CYTARABINE; DAUNORUBICIN; DRUG COSTS; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HOSPITAL COSTS; HUMANS; KARNOFSKY PERFORMANCE STATUS; LENGTH OF STAY; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 6844237003     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1998.00635.x     Document Type: Article

References (12)

1. de Haes, J.C.J.M., van Knippenberg, F.C.E. & Neijt, J.P. (1990) Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. British Journal of Cancer, 62, 1034-1038.
2. Dombret, H., Chastang, C., Fenaux, P., Reiffers, J., Bordessoule, D., Bouabdallah, R., Mandelli, F., Ferrant, A., Auzanneau, G., Tilly, H., Yver, A., Degos, L., for the AML Cooperative Study Group (1995) A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. New England Journal of Medicine, 332, 1678-1684.
3. Hunt, S.M., McEwen, J. & McKenna, S.P. (1986) Measuring Health Status, pp. 241-245. Croom Helm, London.
4. Keating, M.J., McCredie, K.B., Benjamin, R.S., Brodey, G.P., Zander, A., Smith, T.L. & Freireich, E.J. (1981) Treatment of patients over 50 years of age with acute myelogenous leukemia with a combination of rubidazone and cytosine arabinoside, vincristine and prednisone (ROAP). Blood. 58, 584-590.
5. Liu Yin, J.A., Johnson, P.R.E., Davies, J.M., Flanagan, N.G., Gorst, D.W. & Lewis, M.J. (1991) Mitoxantrone and cytosine arabinoside as first-line therapy in elderly patients with acute myeloid leukaemia. British Journal of Haematology, 79, 415-420.
6. Löwenberg, B., Suciu, S., Archimbaud, E., Ossenkoppele, G., Verhoef, G.E.G., Vellenga, E., Wijermans, P., Berneman, Z., Dekker, A.W., Stryckmans, P., Schouten, H., Jehn, U., Muus, P., Sonneveld, P., Dardenne, M., Zitoun, R., on behalf of EORTC-LCG, and HOVON (1997) Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer (EORTC-LCG) and the Dutch Belgian Hemato-Oncology Cooperative Group (HOVON). Blood, 90, 2952-2961.
7. Löwenberg, B., Zittoun, R., Kerkhofs, H., Jehn, U., Abels, J., Debusscher, L., Cauchie, Ch., Peetermans, M., Solbu, G., Suciu, S. & Stryckmans, P. (1989) On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. Journal of Clinical Oncology, 7, 1268-1274.
8. Stone, R.M., Berg, D.T., George, S.L., Dodge, R.K., Paciucci, P.A., Schulman, P., Lee, E.J., Moore, J.O., Powell, B.L., Schiffer, C.A., for the Cancer and Leukemia Group B (1995) Granulocyte-macrophage colony-stimulating factor alter initial chemotherapy for elderly patients with primary acute myelogenous leukemia. New England Journal of Medicine, 332, 1671-1677.
9. Uyl-de Groot, C.A., Hagenbeek, A., Verdonck, L.F., Löwenberg, B. & Rutten, F.F.H. (1995) Cost-effectiveness of autologous bone marrow transplantation in comparison with CHOP chemotherapy in patients with intermediate- and high-grade non-Hodgkin's lymphoma (NHL). Bone Marrow Transplantation, 16, 463-470.
10. van Hout, B.A. & McDonnell, J. (1991) Estimating a parametric relation between health description and health valuation using the Euroqol instrument. Swedish Institute for Health Economics IHE Working Paper. Lund, pp. 45-59.
11. Vellenga, E., Uyl-de Groot, C.A., de Wit, R., Keizer, H.J., Löwenberg, B., ten Haaft, M.A., de Witte, Th.J.M., Verhagen, C.A.H., Stoter, G.J., Rutten, F.F.H., Mulder, N.H., Smid, W.M. & de Vries, E.G.E. (1996) Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. Journal of Clinical Oncology, 14, 619-627.
12. Yates, J., Glidewell, O., Wiernik, P., Cooper, R., Steinberg, D., Dosik, H., Levy, R., Hoagland, C., Henry, P., Gottlieb, A., Cornell, C., Berenberg, J., Hutchison, J.L., Raich, P., Nissen, N., Ellison, R.R., Frelick, R., James, G.W., Falkson, G., Silver, R.T., Haurani, F., Green, M., Henderson, E., Leone, L. & Holland, J.F. (1982) Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALBG study. Blood, 60, 454-463.